Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study)

Summary

The purpose of this study is to consider the following points in patients with hypertension who complicated by metabolic syndrome for Valsartan basis treatment and an existing, standard treatment. * Blood pressure control * Changing of adiponectin and plasminogen activator inhibitor-1 * Influence metabolizing and cardiac function, etc.

Timeline

Start

2006-06

Primary completion

2009-12

Completion

2009-12

Publications

• Miyata M, Ikeda Y, Nakamura S, Sasaki T, Abe S, Minagoe S, Torii H, Lee S, Tateishi S, Kihara K, Ohba I, Kajiya S, Furusho Y, Hamasaki S, Tei C; Kagoshima Collaborate Trial in Metabolic Syndrome (KACT-MetS) Investigators. Effects of valsartan on fibrinolysis in hypertensive patients with metabolic syndrome. Circ J. 2012;76(4):843-51. doi: 10.1253/circj.cj-12-0153.

Drugs

Indications